235 related articles for article (PubMed ID: 1419816)
41. High-dose mercaptopurine followed by intermediate-dose cytarabine in relapsed acute leukemia.
Lockhart S; Plunkett W; Jeha S; Ramirez I; Zipf T; Cork A; Pinkel D
J Clin Oncol; 1994 Mar; 12(3):587-95. PubMed ID: 8120558
[TBL] [Abstract][Full Text] [Related]
42. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Klumper E; Ossenkoppele GJ; Pieters R; Huismans DR; Loonen AH; Rottier A; Westra G; Veerman AJ
Br J Haematol; 1996 Jun; 93(4):903-10. PubMed ID: 8703824
[TBL] [Abstract][Full Text] [Related]
43. Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
Dhaliwal HS; Shannon MS; Barnett MJ; Prentice HG; Bragman K; Malpas JS; Lister TA
Cancer Chemother Pharmacol; 1986; 18(1):59-62. PubMed ID: 3463435
[TBL] [Abstract][Full Text] [Related]
44. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J; Brunet S; Grañena A; Olivé T; Bueno J; Ribera JM; Petit J; Besses C; Llorente A; Guardia R; Macía J; Rovira M; Badell I; Vela E; Díaz de Heredia C; Vivancos P; Carreras E; Feliu E; Montserrat E; Julía A; Cubells J; Rozman C; Domingo A; Ortega JJ
J Clin Oncol; 1996 Apr; 14(4):1353-63. PubMed ID: 8648394
[TBL] [Abstract][Full Text] [Related]
45. A pilot study of continuous infusion Ara-C in combination with rhG-CSF in relapsed childhood acute myeloid leukemia.
Laver J; Shearer P; Krance R; Hurwitz CA; Srivastava DK; Weinstein HJ; Mirro J
Leuk Lymphoma; 1997 Aug; 26(5-6):589-93. PubMed ID: 9389365
[TBL] [Abstract][Full Text] [Related]
46. Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study. MRC Leukaemia in Adults Working Party.
Rees JK; Gray RG; Wheatley K
Br J Haematol; 1996 Jul; 94(1):89-98. PubMed ID: 8757514
[TBL] [Abstract][Full Text] [Related]
47. Long-term results in non randomized patients with acute myelogenous leukemia: a single institution experience.
Deliliers GL; Annaloro C; Oriani A; Della Volpe A; Boschetti C; Cortelezzi A; Maiolo AT
Ann Ital Med Int; 1998; 13(3):146-51. PubMed ID: 9859570
[TBL] [Abstract][Full Text] [Related]
48. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia.
te Boekhorst PA; Löwenberg B; van Kapel J; Nooter K; Sonneveld P
Leukemia; 1995 Jun; 9(6):1025-31. PubMed ID: 7541095
[TBL] [Abstract][Full Text] [Related]
49. Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
Spinolo JA; Dicke KA; Horwitz LJ; Jagannath S; Zander AR; Auber ML; Spitzer G
Bone Marrow Transplant; 1990 Feb; 5(2):111-8. PubMed ID: 1690035
[TBL] [Abstract][Full Text] [Related]
50. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.
Mayer RJ; Davis RB; Schiffer CA; Berg DT; Powell BL; Schulman P; Omura GA; Moore JO; McIntyre OR; Frei E
N Engl J Med; 1994 Oct; 331(14):896-903. PubMed ID: 8078551
[TBL] [Abstract][Full Text] [Related]
51. The impact of karyotype on remission rates in adult patients with de novo acute myeloid leukemia receiving high-dose cytarabine-based induction chemotherapy.
Mehta J; Powles R; Treleaven J; Swansbury GJ; Kulkarni S; Saso R; Min T; Singhal S
Leuk Lymphoma; 1999 Aug; 34(5-6):553-60. PubMed ID: 10492079
[TBL] [Abstract][Full Text] [Related]
52. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Hurwitz CA; Krance R; Schell MJ; Santana VM; Brenner MK; Ribeirio R; Roberts WM; Mahmoud H; Belt J; Crom W
Leukemia; 1992; 6 Suppl 2():39-43. PubMed ID: 1374492
[TBL] [Abstract][Full Text] [Related]
53. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
54. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
Juliusson G; Höglund M; Karlsson K; Löfgren C; Möllgård L; Paul C; Tidefelt U; Björkholm M;
Br J Haematol; 2003 Dec; 123(5):810-8. PubMed ID: 14632771
[TBL] [Abstract][Full Text] [Related]
55. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
56. High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non M3 acute myelogenous leukemia: impact of cytogenetics on achieving a complete remission.
Stein AS; O'Donnell MR; Slovak ML; Nademanee A; Dagis A; Schmidt GM; Parker PM; Snyder DS; Smith EP; Somlo G; Margolin KA; Arber D; Niland J; Forman SJ
Leukemia; 2000 Jul; 14(7):1191-6. PubMed ID: 10914541
[TBL] [Abstract][Full Text] [Related]
57. Randomized study of individualized induction therapy with or without VCR, and of maintenance of 4 or 12 courses in adult AML: JALSG-AML87. Japan Adult Leukemia Study Group (JALSG).
Ohno R; Kobayashi T; Morishima Y; Hiraoka A; Imai K; Asoh N; Tsubaki K; Tomonaga M; Takahashi I; Kodera K
Leukemia; 1992; 6 Suppl 2():92-5. PubMed ID: 1578954
[TBL] [Abstract][Full Text] [Related]
58. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
[TBL] [Abstract][Full Text] [Related]
59. [Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
Ortega Aramburu JJ; Olivé Oliveras T; Javier Manchón G; Bastida Vila P; Sánchez C; Giralt López J
Sangre (Barc); 1991 Feb; 36(1):7-14. PubMed ID: 1853274
[TBL] [Abstract][Full Text] [Related]
60. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]